The association of taxane resistance genes with the clinical course of ovarian carcinoma

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F13%3A10190964" target="_blank" >RIV/00216208:11110/13:10190964 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/13:10190964 RIV/00216208:11120/13:43907530 RIV/00098892:_____/13:#0000604 RIV/00064203:_____/13:10190964 RIV/75010330:_____/13:00010095

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.ygeno.2013.03.005" target="_blank" >http://dx.doi.org/10.1016/j.ygeno.2013.03.005</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.ygeno.2013.03.005" target="_blank" >10.1016/j.ygeno.2013.03.005</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The association of taxane resistance genes with the clinical course of ovarian carcinoma

Popis výsledku v původním jazyce

Taxane and platinum-based chemotherapy regimens are standard treatment for advanced ovarian carcinoma. Expression levels of putative markers of taxane resistance in carcinoma tissues and paired peritoneal samples (n = 55) and in 16 samples of ovaries without signs of carcinoma were compared with clinical data and the patients' time to progression. KIF14, PRC1, CIT and ABCC1 genes were significantly overexpressed in carcinomas when compared with normal ovarian tissues, while ABCB1 and CASP9 expression was decreased. Associations of protein expression of the proliferation marker Ki-67 with KIF14, PRC1, ABCB1 and CASP2 were found. Lastly, it was discovered that ABCB1 and CASP2 levels associated with FIGO stage and that the CIT level associated with the time to progression of ovarian carcinoma patients (P < 0.0001). In conclusion, ABCB1, CASP2, KIF14, PRC1 and CIT genes seem to associate with surrogate markers of ovarian carcinoma progression and CIT gene associates with therapy outcome.

Název v anglickém jazyce

The association of taxane resistance genes with the clinical course of ovarian carcinoma

Popis výsledku anglicky

Taxane and platinum-based chemotherapy regimens are standard treatment for advanced ovarian carcinoma. Expression levels of putative markers of taxane resistance in carcinoma tissues and paired peritoneal samples (n = 55) and in 16 samples of ovaries without signs of carcinoma were compared with clinical data and the patients' time to progression. KIF14, PRC1, CIT and ABCC1 genes were significantly overexpressed in carcinomas when compared with normal ovarian tissues, while ABCB1 and CASP9 expression was decreased. Associations of protein expression of the proliferation marker Ki-67 with KIF14, PRC1, ABCB1 and CASP2 were found. Lastly, it was discovered that ABCB1 and CASP2 levels associated with FIGO stage and that the CIT level associated with the time to progression of ovarian carcinoma patients (P < 0.0001). In conclusion, ABCB1, CASP2, KIF14, PRC1 and CIT genes seem to associate with surrogate markers of ovarian carcinoma progression and CIT gene associates with therapy outcome.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Genomics

ISSN

0888-7543

e-ISSN

—

Svazek periodika

102

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

6

Strana od-do

96-101

Kód UT WoS článku

000322848500004

EID výsledku v databázi Scopus

—